Targeted drug afatinib tested against HER2-Mutated tumors
NCT ID NCT04439136
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests the drug afatinib in 40 people with advanced cancers (like solid tumors or lymphoma) that have a specific genetic change called a HER2 mutation. Afatinib works by blocking the HER2 protein, which may help stop cancer growth. The study aims to see if the drug can shrink tumors or slow their progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Afatinib (a targeted cancer drug taken as a pill)
- What this could lead to
- If it works, this could provide a treatment option for people with advanced cancers that have HER2 mutations, potentially shrinking tumors or slowing their growth.
- What could go wrong
- This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. Afatinib can cause side effects like diarrhea and skin rash, and the cancer may still progress.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered donor cells could outsmart relapsed myeloma
- Can a new PET tracer reveal hidden immune clues in tumors?
- Can a Triple-Drug cocktail tame resistant myeloma?
- Can a protein calm the immune System's overreaction to cancer treatment?
- A hug in a blanket: could deep pressure calm cancer infusion anxiety?
- Could a strong social circle turn back the clock for transplant survivors?